Nutriband Inc Dossier
Qualitative Analysis
Business overview
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a clinical-stage specialty pharmaceutical company focused on developing advanced transdermal drug delivery systems and abuse-deterrent technologies. The company's primary business is the development of a portfolio of transdermal pharmaceutical products. Its lead product candidate under development is AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system designed to reduce the potential for abuse, misuse, diversion, and accidental exposure of transdermal opioid patches. AVERSA™ technology incorporates aversive agents directly into transdermal patches to deter abuse. Nutriband operates through two primary business segments: Pocono Pharmaceuticals, which relates to a coated products manufacturing entity, and 4P Therapeutics, which performs contract research and development services.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Partnered with Brand Institute, Inc. to select and submit a worldwide commercial brand name and visual identity candidate for its lead product, an abuse-deterrent fentanyl transdermal system, to the FDA and international regulatory agencies.
Expected impact: Establishes a proprietary global brand identity, secures full international intellectual property rights, and helps prevent medication errors caused by look-alike or sound-alike names.
Expanding the consumer wellness footprint of its wholly owned subsidiary, Active Intelligence, by introducing new wearable wellness patches and performance tapes (AI Performance Tape, AI Energy Patches, and AI Sleep) to major national retailers and distributors.
Expected impact: Aims to drive near-term commercial sales and brand visibility through proprietary branded sales and white-label agreements with major retail pharmacy and healthcare channels.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Kindeva is a leading global CDMO that provides the FDA-approved fentanyl patch utilized in AVERSA Fentanyl. Under the formalized exclusive partnership, Kindeva performs commercial manufacturing process scale-up, clinical supply manufacturing for human abuse liability studies, and CMC development to support the NDA.
Terms: Shared development costs. On February 4, 2025, the agreement was amended to reduce the hourly labor rate on the project in exchange for a $3.0 million milestone payment payable to Kindeva upon FDA approval of AVERSA Fentanyl.
Serves as the exclusive distribution partner for Costa Rica, covering AVERSA Fentanyl (upon approval) and all sports tape products manufactured at the Pocono Pharmaceutical / Active Intelligence subsidiary.
Terms: Innomedica is responsible for overseeing and financing all regulatory approvals and marketing efforts in Costa Rica.
Exploring potential collaborations to leverage Qvanta's quantum-AI simulation capabilities, secure high-performance computing infrastructure, and advanced cybersecurity technologies to support Nutriband's research, innovation, and long-term product development.
Terms: Non-binding Letter of Intent signed December 18, 2025; definitive financial terms are subject to negotiation.